NEW YORK, Dec. 22 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that Professor Riccardo Lencioni has joined the Company's Scientific Advisory Board, effective immediately.
"We formed our Scientific Advisory Board in 2008 to advance the development of our Delcath PHP System™ with insight from the leading experts in regional cancer therapies," said Eamonn Hobbs, President and CEO of Delcath. "Professor Lencioni is well known to us at Delcath. He has extensive expertise in treating liver cancers and is a pioneer in the emerging field of interventional oncology. We are confident that he will have a palpable impact on the clinical and regulatory success of our core technology, ongoing R&D, and other key scientific initiatives."
Professor Lencioni is an Associate Professor of Radiology at the University of Pisa in Italy and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University Hospital. He is Chairman of the Membership Committee of the Cardiovascular and Interventional Radiological Society of Europe, and Chairman of the Programme Committee of the European Conference on Interventional Oncology. He is also a member of the Steering Committee of the World Conference on Interventional Oncology, and was a founder of the International Liver Cancer Association, in which he also acts as a member of the Governing Board. Professor Lencioni has been a Visiting Professor at 20 different European, American and Asian universities.
Professor Lencioni earned his medical degree with honors from the University of Pisa, where he is board certified in Radiology and Gastroenterology. Having completed two fellowships in Interventional Radiology, he has served as a faculty member in various residency programs, including Radiology, Surgery and Gastroenterology.
Professor Lencioni has edited seven books and has authored 135 articles in peer-reviewed international journals and 40 book chapters in textbooks of Radiology, Gastroenterology and Surgery. He has been an invited or honorary lecturer for more than 400 international meetings and conferences.
Delcath's Scientific Advisory Board now has five members. In addition to Professor Lencioni, the board includes Professor Alexander M.M. Eggermont, MD, PhD, from the Erasmus University Medical Center in The Netherlands; Doctor Douglas L. Fraker, from the University of Pennsylvania School of Medicine; Doctor Larry Kvols, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida; and Doctor Leonard B. Saltz, from the Memorial Sloan-Kettering Cancer Center and the Weill College of Medicine in New York.
About Delcath Systems, Inc.
Delcath Systems Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
SOURCE Delcath Systems, Inc.
Advertisement
"We formed our Scientific Advisory Board in 2008 to advance the development of our Delcath PHP System™ with insight from the leading experts in regional cancer therapies," said Eamonn Hobbs, President and CEO of Delcath. "Professor Lencioni is well known to us at Delcath. He has extensive expertise in treating liver cancers and is a pioneer in the emerging field of interventional oncology. We are confident that he will have a palpable impact on the clinical and regulatory success of our core technology, ongoing R&D, and other key scientific initiatives."
Advertisement
Professor Lencioni is an Associate Professor of Radiology at the University of Pisa in Italy and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University Hospital. He is Chairman of the Membership Committee of the Cardiovascular and Interventional Radiological Society of Europe, and Chairman of the Programme Committee of the European Conference on Interventional Oncology. He is also a member of the Steering Committee of the World Conference on Interventional Oncology, and was a founder of the International Liver Cancer Association, in which he also acts as a member of the Governing Board. Professor Lencioni has been a Visiting Professor at 20 different European, American and Asian universities.
Professor Lencioni earned his medical degree with honors from the University of Pisa, where he is board certified in Radiology and Gastroenterology. Having completed two fellowships in Interventional Radiology, he has served as a faculty member in various residency programs, including Radiology, Surgery and Gastroenterology.
Professor Lencioni has edited seven books and has authored 135 articles in peer-reviewed international journals and 40 book chapters in textbooks of Radiology, Gastroenterology and Surgery. He has been an invited or honorary lecturer for more than 400 international meetings and conferences.
Delcath's Scientific Advisory Board now has five members. In addition to Professor Lencioni, the board includes Professor Alexander M.M. Eggermont, MD, PhD, from the Erasmus University Medical Center in The Netherlands; Doctor Douglas L. Fraker, from the University of Pennsylvania School of Medicine; Doctor Larry Kvols, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida; and Doctor Leonard B. Saltz, from the Memorial Sloan-Kettering Cancer Center and the Weill College of Medicine in New York.
About Delcath Systems, Inc.
Delcath Systems Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
SOURCE Delcath Systems, Inc.
